Published in Int J Alzheimers Dis on May 08, 2012
HMGB1 in health and disease. Mol Aspects Med (2014) 1.67
Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound. Exp Neurol (2013) 1.19
Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders. Am J Neurodegener Dis (2013) 1.08
Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis. Front Cell Neurosci (2015) 0.80
In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin. Neurobiol Dis (2016) 0.79
HMGB1 Mediates Autophagy Dysfunction via Perturbing Beclin1-Vps34 Complex in Dopaminergic Cell Model. Front Mol Neurosci (2017) 0.75
Inhibitory Effect of Lychee Seed Saponins on Apoptosis Induced by Aβ25-35 through Regulation of the Apoptotic and NF-κB Pathways in PC12 Cells. Nutrients (2017) 0.75
HMGB1, a pathogenic molecule that induces neurite degeneration via TLR4-MARCKS, is a potential therapeutic target for Alzheimer's disease. Sci Rep (2016) 0.75
Impact of Tobacco Smoking and Type-2 Diabetes Mellitus on Public Health: A Cerebrovascular Perspective. J Pharmacovigil (2015) 0.75
HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer's disease. J Neuroinflammation (2016) 0.75
A novel synthetic derivative of squamosamide FLZ inhibits the high mobility group box 1 protein-mediated neuroinflammatory responses in murine BV2 microglial cells. Naunyn Schmiedebergs Arch Pharmacol (2017) 0.75
A Toxic Conformer of Aβ42 with a Turn at 22-23 is a Novel Therapeutic Target for Alzheimer's Disease. Sci Rep (2017) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature (2002) 19.77
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (1996) 19.72
Alzheimer's disease is a synaptic failure. Science (2002) 13.82
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol (2005) 11.57
Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature (1995) 9.39
Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 8.89
Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem (2003) 8.34
Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science (2010) 8.04
Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med (2003) 7.83
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35
The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry (1993) 7.26
Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol (1999) 7.16
A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2001) 6.78
Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron (1994) 6.41
Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron (2006) 6.38
Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science (2001) 6.17
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001) 6.00
Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med (2007) 5.87
Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med (1998) 5.78
Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem (2002) 5.63
Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci (2002) 5.01
Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron (2003) 4.39
Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci (2008) 3.90
Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem (1998) 3.77
Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet (1999) 3.14
Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron (1996) 3.14
New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J (2001) 3.04
RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol (2005) 2.96
Role of toll-like receptor signalling in Abeta uptake and clearance. Brain (2006) 2.70
A molecular model of Alzheimer amyloid beta-peptide fibril formation. J Biol Chem (1999) 2.12
Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J (2007) 1.97
Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol (2001) 1.89
Dystrophic microglia in the aging human brain. Glia (2004) 1.79
High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. J Neurochem (2007) 1.77
Metabolism of amyloid-beta peptide and Alzheimer's disease. Pharmacol Ther (2005) 1.54
Morphologic association between microglia and senile plaque amyloid in Alzheimer's disease. Neurosci Lett (1990) 1.51
Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins. FASEB J (2002) 1.47
Slow degradation of aggregates of the Alzheimer's disease amyloid beta-protein by microglial cells. J Biol Chem (1997) 1.45
Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J Neurochem (2002) 1.40
Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol (2010) 1.31
Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease. Brain Res (1998) 1.26
IL-4-induced selective clearance of oligomeric beta-amyloid peptide(1-42) by rat primary type 2 microglia. J Immunol (2008) 1.16
Microglial transplantation increases amyloid-beta clearance in Alzheimer model rats. FEBS Lett (2007) 1.07
HMGB1 inhibitor glycyrrhizin attenuates intracerebral hemorrhage-induced injury in rats. Neuropharmacology (2011) 1.04
Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J Biol Chem (2010) 1.04
High mobility group box protein-1 inhibits microglial Abeta clearance and enhances Abeta neurotoxicity. J Neurosci Res (2004) 0.96
Involvement of WAVE accumulation in Abeta/APP pathology-dependent tangle modification in Alzheimer's disease. Am J Pathol (2009) 0.93
Amphoterin includes a sequence motif which is homologous to the Alzheimer's beta-amyloid peptide (Abeta), forms amyloid fibrils in vitro, and binds avidly to Abeta. Biochemistry (2001) 0.87
Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration. Eur J Neurosci (2007) 0.86
Involvement of Wiskott-Aldrich syndrome protein family verprolin-homologous protein (WAVE) and Rac1 in the phagocytosis of amyloid-beta(1-42) in rat microglia. J Pharmacol Sci (2003) 0.85
Role of high mobility group protein-1 (HMG1) in amyloid-beta homeostasis. Biochem Biophys Res Commun (2003) 0.85
Possible involvement of small oligomers of amyloid-beta peptides in 15-deoxy-delta 12,14 prostaglandin J2-sensitive microglial activation. J Pharmacol Sci (2003) 0.83
Heat shock protein-90-induced microglial clearance of exogenous amyloid-beta1-42 in rat hippocampus in vivo. Neurosci Lett (2003) 0.80
White matter lesions and glial activation in a novel mouse model of chronic cerebral hypoperfusion. Stroke (2004) 2.29
Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity. Neuron (2007) 2.08
NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood (2005) 1.67
Histone deacetylase SIRT1 modulates neuronal differentiation by its nuclear translocation. Proc Natl Acad Sci U S A (2008) 1.62
Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J Biol Chem (2005) 1.61
Functional CD5+ B cells develop predominantly in the spleen of NOD/SCID/gammac(null) (NOG) mice transplanted either with human umbilical cord blood, bone marrow, or mobilized peripheral blood CD34+ cells. Exp Hematol (2003) 1.49
PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson's disease rat model. Neurobiol Dis (2006) 1.47
Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins. FASEB J (2002) 1.47
Nardilysin prevents amyloid plaque formation by enhancing α-secretase activity in an Alzheimer's disease mouse model. Neurobiol Aging (2013) 1.46
Proteasome inhibitors protect against degeneration of nigral dopaminergic neurons in hemiparkinsonian rats. J Pharmacol Sci (2005) 1.45
Correlation of bite force with excitation-contraction coupling time of the masseter in myasthenia gravis. Clin Neurophysiol (2010) 1.43
Hypersomnia caused by isolated angiitis of the CNS. Intern Med (2005) 1.42
Contribution of anti-ryanodine receptor antibody to impairment of excitation-contraction coupling in myasthenia gravis. Clin Neurophysiol (2011) 1.40
[A case of status epilepticus with a possible therapeutic effect by dantrolene sodium]. Rinsho Shinkeigaku (2011) 1.40
Photoinitiators enhanced 1,2-dichloropropane-induced cytotoxicity in human normal embryonic lung fibroblasts cells in vitro. Environ Sci Pollut Res Int (2014) 1.39
Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J Neurochem (2007) 1.34
Cerebral hypoperfusion accelerates cerebral amyloid angiopathy and promotes cortical microinfarcts. Acta Neuropathol (2011) 1.34
Transcription and translation products of the cytolysin gene psm-mec on the mobile genetic element SCCmec regulate Staphylococcus aureus virulence. PLoS Pathog (2011) 1.34
Selective impairment of working memory in a mouse model of chronic cerebral hypoperfusion. Stroke (2007) 1.34
Clonally amplified cardiac stem cells are regulated by Sca-1 signaling for efficient cardiovascular regeneration. J Cell Sci (2007) 1.33
Loss of HRD1-mediated protein degradation causes amyloid precursor protein accumulation and amyloid-beta generation. J Neurosci (2010) 1.33
Matrix metalloproteinase-2 plays a critical role in the pathogenesis of white matter lesions after chronic cerebral hypoperfusion in rodents. Stroke (2006) 1.26
Targeting the Wnt/β-catenin signaling pathway in human cancers. Expert Opin Ther Targets (2011) 1.25
Disease model: Parkinson's disease. Trends Mol Med (2003) 1.24
Characterization of sequential N-cadherin cleavage by ADAM10 and PS1. Neurosci Lett (2006) 1.22
Reconstruction of dopaminergic neural network and locomotion function in planarian regenerates. Dev Neurobiol (2007) 1.22
Axonal damage and demyelination in the white matter after chronic cerebral hypoperfusion in the rat. Brain Res (2002) 1.21
Zoledronic acid - a multiplicity of anti-cancer action. Curr Med Chem (2007) 1.21
Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci Lett (2002) 1.20
Association of the cytoskeletal GTP-binding protein Sept4/H5 with cytoplasmic inclusions found in Parkinson's disease and other synucleinopathies. J Biol Chem (2003) 1.19
Human cardiac stem cells exhibit mesenchymal features and are maintained through Akt/GSK-3beta signaling. Biochem Biophys Res Commun (2006) 1.17
Mobile genetic element SCCmec-encoded psm-mec RNA suppresses translation of agrA and attenuates MRSA virulence. PLoS Pathog (2013) 1.16
Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism. Brain Res (2007) 1.14
Neuroprotective effects of quercetin and rutin on spatial memory impairment in an 8-arm radial maze task and neuronal death induced by repeated cerebral ischemia in rats. J Pharmacol Sci (2007) 1.14
Proteomic pattern analysis discriminates among multiple sclerosis-related disorders. Ann Neurol (2012) 1.14
Two cases of ductal adenoma of the breast. Breast Cancer (2006) 1.14
Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer's and Parkinson's diseases. J Alzheimers Dis (2011) 1.13
ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br J Haematol (2007) 1.13
Chronic cerebral hypoperfusion accelerates amyloid beta deposition in APPSwInd transgenic mice. Brain Res (2009) 1.13
Cortical microinfarcts in Alzheimer's disease and subcortical vascular dementia. Neuroreport (2009) 1.11
A mouse model characterizing features of vascular dementia with hippocampal atrophy. Stroke (2010) 1.11
Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc Natl Acad Sci U S A (2011) 1.10
Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood (2005) 1.10
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease. J Biol Chem (2006) 1.10
Nardilysin regulates axonal maturation and myelination in the central and peripheral nervous system. Nat Neurosci (2009) 1.08
Microglial transplantation increases amyloid-beta clearance in Alzheimer model rats. FEBS Lett (2007) 1.07
High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal. J Biol Chem (2001) 1.07
Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res (2008) 1.06
Intraneuronal amyloid beta accumulation and oxidative damage to nucleic acids in Alzheimer disease. Neurobiol Dis (2009) 1.06
Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models. J Neurosci Res (2009) 1.05
Selective white matter abnormalities in a novel rat model of vascular dementia. Neurobiol Aging (2011) 1.05
DJ-1 protects against neurodegeneration caused by focal cerebral ischemia and reperfusion in rats. J Cereb Blood Flow Metab (2007) 1.05
"Burst and slow complexes" in nonconvulsive epileptic status. Epileptic Disord (2006) 1.05
Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions. J Biol Chem (2003) 1.04
Toxin-induced and genetic animal models of Parkinson's disease. Parkinsons Dis (2010) 1.04
Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J Biol Chem (2010) 1.04
Environmental enrichment ameliorated high-fat diet-induced Aβ deposition and memory deficit in APP transgenic mice. Neurobiol Aging (2011) 1.04
Apoptosis signal-regulating kinase 1 is a novel target molecule for cognitive impairment induced by chronic cerebral hypoperfusion. Arterioscler Thromb Vasc Biol (2013) 1.03
GSK3beta activity modifies the localization and function of presenilin 1. J Biol Chem (2007) 1.02
Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer. Cancer Sci (2012) 1.01
Myeloid-derived suppressor cells play crucial roles in the regulation of mouse collagen-induced arthritis. J Immunol (2013) 1.01
Bone marrow angiotensin AT1 receptor regulates differentiation of monocyte lineage progenitors from hematopoietic stem cells. Arterioscler Thromb Vasc Biol (2009) 1.01
Painful neck on rotation: diagnostic significance for crowned dens syndrome. J Neurol (2010) 1.01
Upregulation of ceramide and its regulating mechanism in a rat model of chronic cerebral ischemia. Brain Res (2004) 1.00
Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity. Biochem Biophys Res Commun (2004) 0.99
Granulocyte colony-stimulating factor-mobilized circulating c-Kit+/Flk-1+ progenitor cells regenerate endothelium and inhibit neointimal hyperplasia after vascular injury. Arterioscler Thromb Vasc Biol (2006) 0.99
Fractalkine-upregulated milk-fat globule EGF factor-8 protein in cultured rat microglia. J Neuroimmunol (2005) 0.99
Zoledronic acid significantly enhances radiation‑induced apoptosis against human fibrosarcoma cells by inhibiting radioadaptive signaling. Int J Oncol (2012) 0.99
Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase. Arthritis Rheum (2007) 0.99
Oxidative stress induction of DJ-1 protein in reactive astrocytes scavenges free radicals and reduces cell injury. Oxid Med Cell Longev (2010) 0.99
Combined effects of bisphosphonate and radiation on osteosarcoma cells. Anticancer Res (2010) 0.98
The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol (2007) 0.98
Immunohistochemical evaluation of hormone receptors in breast cancer: which scoring system is suitable for highly sensitive procedures? Appl Immunohistochem Mol Morphol (2004) 0.98
Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. Free Radic Biol Med (2005) 0.98
Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. J Rheumatol (2007) 0.98
Blood-brain barrier disruption in white matter lesions in a rat model of chronic cerebral hypoperfusion. J Cereb Blood Flow Metab (2002) 0.97
Blood-brain barrier is impaired in the hippocampus of young adult spontaneously hypertensive rats. Acta Neuropathol (2004) 0.97
Attenuation of brain damage and cognitive impairment by direct renin inhibition in mice with chronic cerebral hypoperfusion. Hypertension (2011) 0.97
alpha-Synuclein is colocalized with 14-3-3 and synphilin-1 in A53T transgenic mice. Acta Neuropathol (2006) 0.96
Significance of C4d staining in ABO-identical/compatible liver transplantation. Mod Pathol (2007) 0.96
Exercise is more effective than diet control in preventing high fat diet-induced β-amyloid deposition and memory deficit in amyloid precursor protein transgenic mice. J Biol Chem (2012) 0.96
Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells. Blood (2010) 0.96
Neuroprotective properties of Bcl-w in Alzheimer disease. J Neurochem (2004) 0.96
High mobility group box protein-1 inhibits microglial Abeta clearance and enhances Abeta neurotoxicity. J Neurosci Res (2004) 0.96
Apoptotic promoters and inhibitors in Alzheimer's disease: Who wins out? Prog Neuropsychopharmacol Biol Psychiatry (2003) 0.95
Fully automated and super-rapid system for the detection of JAK2V617F mutation. Leuk Res (2008) 0.95
Transgenic mice expressing mutant (N279K) human tau show mutation dependent cognitive deficits without neurofibrillary tangle formation. FEBS Lett (2005) 0.95